Ftse Mib
38.366,87
1,03%
DAX
22.716,54
1,04%
S&P 500
6.114,63
-0,01%
NASDAQ
20.026,77
0,41%
Bitcoin
96.799,99
0,69%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mangoceuticals Inc (MGRX) Mangoceuticals Inc (MGRX) Notizie

Mangoceuticals Inc

MGRX
4,85
0,42 (9,48%)
15 Feb 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/2/202522:30EDGAR2Form 8-K - Current report
12/2/202514:00EDGAR2Form 8-K - Current report
12/2/202514:00GLOBEMangoceuticals Advances Antiviral Research on its Patented..
10/2/202523:12EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/2/202523:10EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
07/2/202523:25EDGAR2Form 8-K - Current report
06/2/202522:46EDGAR2Form PRE 14A - Other preliminary proxy statements
06/2/202513:00GLOBEMangoceuticals Advances H1N1 Efficacy Study Noting..
03/2/202514:30GLOBEMangoceuticals, Inc. Executes Exclusive Distribution..
31/1/202523:25EDGAR2Form 8-K - Current report
22/1/202523:28EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
21/1/202522:30EDGAR2Form 8-K - Current report
15/1/202522:30EDGAR2Form 8-K - Current report
08/1/202522:30EDGAR2Form 8-K - Current report
26/12/202422:30EDGAR2Form 8-K - Current report
19/12/202423:33GLOBEMangoceuticals, Inc. Completes Acquisition of Mushroom-Based..
19/12/202423:30EDGAR2Form 8-K - Current report
06/12/202423:15EDGAR2Form 8-K - Current report
04/12/202413:00GLOBEMangoceuticals, Inc. Initiates Investigation into Potential..
14/11/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202423:04EDGAR2Form 8-K - Current report
31/10/202413:00EDGAR2Form 8-K - Current report
31/10/202413:00GLOBEMangoceuticals, Inc. Regains Full Compliance with Nasdaq..
25/10/202423:00EDGAR2Form 8-K - Current report
22/10/202414:00EDGAR2Form 8-K - Current report
22/10/202414:00GLOBEMangoRx Announces Formation of Strategy and Alternatives..
21/10/202423:10EDGAR2Form 8-K - Current report
21/10/202423:10GLOBEMangoRx Responds to and Refutes Recent Claims Made by Eli..
11/10/202423:15GLOBEMANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK..
03/10/202414:30GLOBEMangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist..
01/10/202419:05APSHealthcare Shares Rise Following Product Availability..
01/10/202413:30GLOBEMangoRx Addresses $49.3 Billion Global GLP-1 Market With..
15/8/202415:25GLOBEMangoRx Reports 1,685% Increase in Shareholders’ Equity From..
13/8/202422:00GLOBEMangoRx Receives Certificate of Grant in India for its..
09/8/202414:15GLOBEMangoRx Completes Migration to DEA-Approved Telemedicine..
24/7/202414:15GLOBEMangoRx Initiates Efficacy Studies on its Patented..
18/7/202422:05GLOBEMangoceuticals CEO Jacob Cohen Featured on Benzinga..
16/7/202414:20GLOBEMangoRx Secures DEA Approval for Proprietary HIPAA-Compliant..
12/7/202419:30GLOBEMangoRx Appoints Dr. Douglas Christianson, N.D. as Director..
11/7/202414:15GLOBEMangoRx Announces Strategic Partnership for Expansion into..
18/6/202420:57EDGAR2Form 144 - Report of proposed sale of securities
10/6/202419:28EDGAR2Form 144 - Report of proposed sale of securities
06/6/202414:30GLOBEMangoRx Receives Notice of Acceptance for Patent Application..
05/6/202423:15EDGAR2Form 8-K - Current report
05/6/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:00GLOBEMangoRx Receives Patent Notice of Allowance in Japan for..
04/6/202414:00GLOBEMangoRx to Introduce “MOJO” Pharmaceutical Compounded..
28/5/202414:30GLOBEMangoceuticals, Inc. Announces Completion of First Batch of..
23/5/202414:30GLOBEMangoRx Engages Renown International Digital and Performance..
Apertura: 4,515 Min: 4,3215 Max: 4,90
Chiusura: 4,43

La tua Cronologia

NASDAQ
MGRX
Mangoceuticals
BIT
UB82DQ
Unicredit Bank
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci